S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Maricann Group Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume682,578 shs
Average Volume142,686 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company's services a patient base with more than 8,000 registered patients. The Company is undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.
Maricann Group logo


Overall MarketRank

1.10 out of 5 stars

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive MARI News and Ratings via Email

Sign-up to receive the latest news and ratings for MARI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Maricann Group (CNSX:MARI) Frequently Asked Questions

Is Maricann Group a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Maricann Group in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Maricann Group stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MARI, but not buy additional shares or sell existing shares.
View analyst ratings for Maricann Group
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Maricann Group?

Wall Street analysts have given Maricann Group a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Maricann Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for MARI?

1 equities research analysts have issued 12-month price objectives for Maricann Group's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Maricann Group's share price to reach $4.00 in the next year.
View analysts' price targets for Maricann Group
or view Wall Street analyst' top-rated stocks.

What other stocks do shareholders of Maricann Group own?

Who are Maricann Group's key executives?

Maricann Group's management team includes the following people:
  • Paul Pathak, Interim Chairman of the Board (Age 49)
  • Michael B. Stein, President, Director
  • Ben Ward, Chief Executive Officer, Interim Chief Financial Officer
  • Geoff Kosar, Vice President - Sales and Marketing

What is Maricann Group's stock symbol?

Maricann Group trades on the CNSX under the ticker symbol "MARI."

How do I buy shares of Maricann Group?

Shares of MARI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Maricann Group's official website?

The official website for Maricann Group is www.maricann.com.

How can I contact Maricann Group?

Maricann Group's mailing address is 845 Harrington Crt Unit 3, BURLINGTON, ON L7N 3P3, Canada. The company can be reached via phone at +1-289-2886284.

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.